ALNY vs. CVS: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and CVS, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
CVS stands out with 78.57 billion USD in market value—about 2.06× ALNY’s market cap of 38.15 billion USD.
CVS carries a higher beta at 0.60, indicating it’s more sensitive to market moves, while ALNY remains steadier at 0.17.
| Symbol | ALNY | CVS |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | CVS Health Corporation |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Healthcare Plans |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Mr. J. David Joyner CEBS |
| Price | 292.58 USD | 62.11 USD |
| Market Cap | 38.15 billion USD | 78.57 billion USD |
| Beta | 0.17 | 0.60 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | November 20, 1996 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALNY and CVS over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALNY and CVS based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALNY posts a negative P/E of -140.68, reflecting last year’s net loss, while CVS at 14.83 signals healthy earnings.
- ALNY posts a negative forward PEG of -38.16, hinting at anticipated earnings decline, whereas CVS at 1.27 has projections for stable or growing earnings.
- ALNY has a negative Price-to-Free Cash Flow ratio of -506.05, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, CVS (P/FCF 13.23) indicates positive free cash flow generation.
| Symbol | ALNY | CVS |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -140.68 | 14.83 |
| Forward PEG Ratio (TTM) | -38.16 | 1.27 |
| Price-to-Sales Ratio (P/S, TTM) | 16.25 | 0.21 |
| Price-to-Book Ratio (P/B, TTM) | 328.68 | 1.02 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -506.05 | 13.23 |
| EV-to-EBITDA (TTM) | -251.73 | 10.98 |
| EV-to-Sales (TTM) | 16.37 | 0.40 |
| EV-to-Free Cash Flow (TTM) | -509.80 | 25.20 |
Dividend Comparison
ALNY offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while CVS provides a 4.28% dividend yield, giving investors a steady income stream.
| Symbol | ALNY | CVS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.28% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALNY and CVS, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- CVS’s current ratio of 0.82 indicates its assets may not cover near-term debts, whereas ALNY at 3.04 maintains healthy liquidity.
- CVS posts a quick ratio of 0.63, indicating limited coverage of short-term debts from its most liquid assets—while ALNY at 2.98 enjoys stronger liquidity resilience.
- ALNY is heavily leveraged (debt-to-equity ratio 11.28), which can boost returns but raises risk if borrowing costs climb, while CVS at 1.06 keeps leverage at a more moderate level.
- With negative EBIT (-0.79), ALNY cannot cover its interest payments. CVS, with an interest coverage of 3.18, meets its interest obligations.
| Symbol | ALNY | CVS |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 0.82 |
| Quick Ratio (TTM) | 2.98 | 0.63 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 1.06 |
| Debt-to-Assets Ratio (TTM) | 0.31 | 0.32 |
| Interest Coverage Ratio (TTM) | -0.79 | 3.18 |